YKYasar Karaaslan

Yasar Karaaslan

*This is an algorithmically generated author record based on publicly available information.

Yasar Karaaslan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Decreased Chitotriosidase Activity and Levels in Familial Mediterranean Fever

    by Halef Okan Doğan, Ahmet Omma, Turan Turhan, Nihal Boğdaycıoğlu, Yaşar Karaaslan, Hayrettin Yavuz, Özlem Demirpençe, Hüseyin Aydın, Sevtap Bakır

    Doğan HO, et al. J Korean Med Sci. 2016 Dec;31(12):1902-1906. https://doi.org/10.3346/jkms.2016.31.12.1902


  • Open Access

    Can the mean platelet volume be a predictor of disease activity in primary Sjogren syndrome?

    by Ahmet Omma, Orhan Kucuksahin, Sevinc Sandikci, Bahar Ozdemir, Sukran Erten, Yasar Karaaslan


  • AB0669 The Importance of Serum Visfatin Levels in Behcet's Disease Patients

    by M.E. Enecik, Z. Ozbalkan, G. Keskin, Y. Karaaslan

    Background It's a known fact that serum levels of the tumor necrosis factor Alfa (TNF-α) interleucin-6 (IL-6) and other proinflammatory cytokines which are released from the adipose tissue are increased in Behcet's disease (BD). In BD adipose tissue is not a passive energy depot, it is an active endocrine organ and releases adipositokines. Visfatine is one of them. Visfatin is related to TNF-α and IL-6, IL-1 beta, co-stimulators like CD40, CD54, CD 80 and endothelial ICAM-1 and ICAM-2. We aimed to search the relation among levels of serum visfatin in BD activity. Methods 60BD patients (30 in active state and 30 in remission) who were diagnosed according to The Criteria of Working Group on International BD and 20 healthy subjects as controls were involeved in to the study. Serum visfatin levels were compared in between three groups. Results Visfatin levels were significantly higher in both group of patients compared to the healthy control group (both pConclusions Serum visfatin levels in BD patients with active and inactive states are higher than the healthy control group. That could be concluded as visfatin as a proinflammatory cytokines have a role in chronic inflammatory reactions and sustains the cellular expression of the inflammatory cytokines in BD. References Samara A, Clin Endocrinol (Oxf). 2008;29. Moschen AR, J Immunol. 2007;178:1748-1758. Yazici H, Curr Opin Rheumatol. 2001; 13:18-22. Sahin M, Ann Clin Lab Sci. 2006; 36:449-454. Moschen AR, J Immunol. 2007;178:1748-1758. 6- Samara AClin Endocrinol (Oxf). 2008;29. Disclosure of Interest None declared

  • Association of the PTPN22 gene polymorphism with autoantibody positivity in Turkish rheumatoid arthritis patients

    by A. Ates, Y. Karaaslan, E. Karatayli, E. Ertuğrul, S. Aksaray, A. Türkyilmaz, G. Özet

    The PTPN22 C1858T gene polymorphism has been recently reported to be associated with rheumatoid arthritis (RA) in European and North American ancestry. In contrast, the frequency of PTPN22 C1858T polymorphism is extremely rare in Asian and African populations. As the genetic heterogeneity between populations is clearly present in RA, we wanted to investigate whether the PTPN22 C1858T polymorphism is associated with RA in Turkey and with autoantibody positivity. A total of 323 RA patients and 426 healthy controls were genotyped by polymerase chain reaction restriction fragment length polymorphism for the PTPN22 C1858T polymorphism (rs2476601). The frequencies of heterozygote genotype (CT) were 8.4% in RA patients and 5.4% in the healthy controls, respectively [odds ratio (OR): 1.6, P = 0.14]. The homozygote genotype (T/T) was absent in both RA patients and the healthy controls. When compared with the healthy controls, we found the significant associations between the frequency of PTPN22 heterozygote (CT) polymorphism and RA patients with RF positivity and anti‐CCP positivity, respectively (OR: 2.05, P = 0.04 and OR: 2.1, P = 0.03, respectively). Our study suggests that the PTPN22 C1858T polymorphism acts as a susceptibility gene for autoantibody‐positive RA in Turkey.


  • Alterations in Left Ventricular Function in Patients with Behçet’s Disease Using Radionuclide Ventriculography and Doppler Echocardiography

    by Meral Calguneri, Belkis Erbas, Sirri Kes, Yasar Karaaslan

    Behçet’s syndrome is a multisystem disease; however, cardiac involvement in this disorder has been relatively less recognized. Noninvasive imaging methods may reveal a cardiac disorder which has not manifested itself clinically. In this study, radionuclide ventriculography and Doppler echocardiography were performed in 24 patients with Behçet’s disease to assess the left ventricular systolic and diastolic function. Patients had neither known heart disease nor cardiac symptoms. Radionuclide ventriculography was performed using 99mTc-labeled red blood cells. Ejection fraction (EF), EF fraction in the first 100 ms (EFV), peak ejection rate, time to peak ejection, 1/3 EF, time to end systole, peak filling rate (PFR), time to peak filling and 1/3 filling fraction (1/3 FF) values were computed using Fourier analysis of the time activity curve of the left ventricle with 3 harmonics. Doppler echocardiography (DE) has described impairment of diastolic compliance using analysis of mitral flow. The mean EF (54.7 ± 9%), EFV (11.6 ± 3.6%), PFR (2.49 ± 0.58 EDC/s) and 1/3 FF (33.64 ± 14%) values were significantly lower in patients than those of the control group. Nine (37.5%) patients demonstrated an impairment of diastolic function and 3 (12.5%) had abnormal systolic function observed by the radionuclide method. DE showed abnormal ventricular compliance in 13.6% of patients. As a conclusion, noninvasive imaging methods such as radionuclide ventriculography and DE may be valuable to detect diastolic impairment as an early sign of cardiac involvement in Behçet’s disease.